glp-1 obesity market news today Home Delivery Injectables | Global Market Analysis Report GLP-1 Drugs Market Size to

We just published data showing that members on GLP-1 therapy who received concurrent nutrition support saved $168 PMPM more than matched members on GLP-1s alone

As of early 2026, several potent single, dual, and triple incretin receptor agonists are in Phase 2/3 trials for MASH including : Survodutide : A dual glucagon (GCGR)/GLP-1 receptor agonist that has shown significant MASH resolution in Phase 2 trials

Developing drugs for metabolic dysfunction-associated steatohepatitis (MASH) has been a surprisingly challenging task

A better understanding is urgently needed to address the root cause of obesity stigma, which manifests in our misperceptions of obesity.16 This understanding must lead to definitive actions that provide equality to the treatment of obesity within a chronic disease framework, one in which PwO will not be discriminated against and will be equally supported

Find pharmacies, manage your prescriptions and save money.